United States · Series A startup

Who invested in NeuroEM

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Medical Devices

Funding summaryUpdated 26 Oct 2026

$1.3Mraised across 1 round since 2025, from 1 source

Latest round
Series A, $1.3MJun 2025
Investors
1
See who backed them

The rounds

  1. Jun 2025
    Series A$1.3M

    Source recorded

Founders and team

From NeuroEM's own website: 9 on the team.

  • Chuck PapageorgiouChief Executive & Technical Officer
  • Amanda PatanowChief Product
  • Marilyn ThompsonChief Financial Officer
  • Rob BaranowskiChief Engineer
  • Sam Alex MulderChief of Staff
  • Tracy IngramChief Operating & Information Officer
  • Jamie RutledgeDirector
  • Jonathan GordonChairman of the Board
  • William J. BurginDirector

Everyone who backed them

New York AngelsAngel network1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists NeuroEM as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

Bluelake VenturesVC firmPer its own site

Quick answers about NeuroEM

Who invested in NeuroEM?

NeuroEM's investors include New York Angels.

How much has NeuroEM raised?

NeuroEM has raised $1.3M across 1 round since 2025.

When did NeuroEM last raise?

NeuroEM's most recent round was a Series A of $1.3M in Jun 2025.

What was NeuroEM's biggest round?

Its most recent round, $1.3M in Jun 2025, is also its largest on record.

Who backed NeuroEM first?

NeuroEM's first round on record, in Jun 2025, was backed by New York Angels.

What stage is NeuroEM at?

NeuroEM's latest named round is a Series A, in Jun 2025.

Where is NeuroEM based?

NeuroEM is based in the United States.

Companies like NeuroEM

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.